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Author Summary: Abstract and Brief Discussion
Background
Gemcitabine and docetaxel have a broad spectrumof clinical activity in patientswith carcinoma. The SarcomaAlliance for
Research Through Collaboration conducted a phase II trial of gemcitabine in combination with docetaxel in children and
adults with recurrent Ewing sarcoma (EWS), osteosarcoma (OS), or unresectable or recurrent chondrosarcoma. The pri-
mary objectivewas to determine the objective response rate using Response Evaluation Criteria in Solid Tumors (RECIST).
Methods
Gemcitabine (675mg/m2 i.v. over 90minutesondays1and8)wasadministered in combinationwithdocetaxel (75mg/m2
i.v. over1houronday8)every21days.All patients received filgrastimorpegfilgrastim.ABayesian formulationwasused to
determine theprobability of achieving the target response rate ineach subtype—0.35 for EWSandOSor0.20 for chon-
drosarcoma. If the probability of achieving the target response ratewas0.05, the combinationwas considered inac-
tive. Toxicity was graded according to Common Terminology Criteria for Adverse Events (CTCAE), version 3.0.
Results
Fifty-three eligible patients were enrolled into three subtype groups—OS (n14), EWS (n14), and chondrosarcoma
(n25). Toxicities included neutropenia, thrombocytopenia, fatigue, dyspnea, bronchospasm, edema, neuropathy,
and liver functionabnormalities.Dosemodification for toxicitywas required for eight patients during cycle 1and16pa-
tients in subsequent cycles. Seven patients withdrew from therapy due to toxicity. No complete responses were ob-
served. Partial responseswere observed in OS (n1), EWS (n2), and chondrosarcoma (n2) patients.
Conclusions
Gemcitabine in combination with docetaxel was associated with a probability of reaching the target 35% response rate of
5% inOS patients and 5.6% in EWSpatients; the probability of reaching a 20% response rate in chondrosarcomapatients
was14%.
Trial Information
Disease: Sarcomas – Adult
Disease: Pediatric cancer – Osteosarcoma
Disease: Pediatric cancer – Ewings
Stage of disease / treatment: Metastatic / Advanced
Prior Therapy: 2 prior regimens
Type of study – 1: Phase II
Type of study – 2: Single arm
Additional Details of Endpoints or Study Design:
TumorswereevaluatedbyRECISTatbaselineandprior to cycle3, 5, 7, 9, 13, 15 thenprior toevery4th cycleof therapy.
Statistical Design:ABayesian formulationwas used to estimate the probability of achieving the target objective response rate in
each subtype. Under a Bayesian formulation, the priormeans reflect the targeted values (threshold interesting response rate) of
0.35 in Ewing andosteosarcoma subtypes and0.20 in the chondrosarcoma subtype. At eachevaluation, thepatient’s diseasewas
categorized as RCR/PR (complete or partial response), Fprogressive disease or death (failure), or S (stable diseaseneither
Rnor F). ApatientwithoutcomeRor F at any stagewas scoredashaving that overall outcome,while apatientwithoutcomeSwas
re-evaluated after subsequent cycles of therapy. A generalized logistic model assuming pj,k exp(hj,k)/{1 exp(hR,k) ex-
p(hF,k)} for jRor F,with pS,k 1/{1 exp(hR,k) exp(hF,k)}was used. The overall probability of outcome jRor F over 4 eval-
uations is givenexplicitly by xj,4pj,1pS,1 pj,2pS,1 pS,2 pj,3pS,1 pS,2 pS,3 pj,4.Weassumeda .50probability of S in each
stage,with the stageeffects assuming if a patient responded in4evaluations (prior to cycle 9), then theprobabilities that it occurs
in evaluation 1, 2, 3 or 4were .70, .10, .05, .05, respectively.
Investigator’s Assessment of Activity: Inactive
Drug Information
Drug 1:
Generic/Working name: Gemcitabine
Trade name: N/A
Drug type: Small molecule
Drug class: Antimetabolite
Dose: 675milligrams (mg) per squaredmeter (m2)
Route: IV
Schedule of Administration: Over 90minutes on days 1 and day 8 every 21 days
Drug 2:
Generic/Working name: Docetaxel
Trade name: N/A
Drug type: Small molecule
Drug class: Microtubule-targeting agent
Dose: 75milligrams (mg) per squaredmeter (m2)
Route: IV
Schedule of Administration: Over 1 hour on day 8 every 21 days
Patient Characteristics
Number of patients,male: 33
Number of patients, female: 20
Stage: Not Collected
Age: Median (range): 37.7 (12.9–77.6)
Number of prior systemic therapies: Median (range): 1 (0–3)
Performance Status: ECOG: Not Collected
Other: BetweenMay 2005 and September 2009, 54 subjects were enrolled at 11
participating sites. One patient with chondrosarcomawas ineligible due to lack of
measurable disease at enrollment. All patients havemet criteria for discontinuation
of protocol therapy.
Cancer Types or Histologic Subtypes
Osteosarcoma 14
Ewings Sarcoma 14
Chondrosarcoma 25
Primary AssessmentMethod
Experimental Arm: Chondrosarcoma
Number of patients screened: N/A
Number of patients enrolled: 26
Number of patients evaluable for toxicity: 25
Number of patients evaluated for efficacy: 25
Evaluationmethod: RECIST 1.0
Response assessment CR: 0%
Response assessment PR: 8%
Response assessment SD: 56%
Response assessment PD: 36%
Response assessment other:
(Median) duration assessments PFS: N/A
(Median) duration assessments TTP: N/A
(Median) duration assessments OS: N/A
(Median) duration assessments response duration: N/A
(Median) duration assessments duration of treatment: 12weeks
Experimental Arm: Ewings Sarcoma
Number of patients screened: N/A
Number of patients enrolled: 14
Number of patients evaluable for toxicity: 14
Number of patients evaluated for efficacy: 14
Evaluationmethod: RECIST 1.0
Response assessment CR: 0%
Response assessment PR: 14%
Response assessment SD: 43%
Response assessment PD: 43%
Response assessment other:
(Median) duration assessments PFS: N/A
(Median) duration assessments TTP: N/A
(Median) duration assessments OS: N/A
(Median) duration assessments response duration: N/A
(Median) duration assessments duration of treatment:6weeks
Experimental Arm: Osteosarcoma
Number of patients screened: N/A
Number of patients enrolled: 14
Number of patients evaluable for toxicity: 14
Number of patients evaluated for efficacy: 14
Evaluationmethod: RECIST 1.0
Response assessment CR: 0%
Response assessment PR: 7%
Response assessment SD: 21%
Response assessment PD: 72%
Response assessment other:
(Median) duration assessments PFS: N/A
(Median) duration assessments TTP: N/A
(Median) duration assessments OS: N/A
(Median) duration assessments response duration: N/A
(Median) duration assessments duration of treatment:6weeks
Experimental Arm: Total Patient Population
Number of patients screened: N/A
Number of patients enrolled: 53
Number of patients evaluable for toxicity: 53
Number of patients evaluated for efficacy: 53
Evaluationmethod: RECIST 1.0
Response assessment CR: 0%
Response assessment PR: 9%
Response assessment SD: 49%
Response assessment PD: 42%
Response assessment other:
(Median) duration assessments PFS: N/A
(Median) duration assessments TTP: N/A
(Median) duration assessments OS: N/A
(Median) duration assessments response duration: N/A
(Median) duration assessments duration of treatment:9weeks
Adverse Events
Name *NC/NA 1 2 3 4 5 All Grades
*No Change fromBaseline/No Adverse Event
Serious Adverse Events
Name Grade Attribution
Infection/Cellulitis 3 Unrelated
Infection/Cellulitis 3 Probable
Pneumonitis 3 Possible
Pain/Back 3 Unrelated
Myositis/Radiation recall 3 Probable
Anemia requiring hospitalization 3 Possible
Disease progression/Death 5 Unrelated
Pericardial effusion 3 Probable
Cardiac tamponade 3 Unrelated
Infection/Pneumonia 3 Unrelated
Progressive disease 4 Unrelated
Hemoptysis 3 Unrelated
Pneumonitis/Pneumonia 3 Possible
Pharmacokinetics/Pharmacodynamics
N: Not Collected
Cmax: Not Collected
AUC: Not Collected
Half-life: Not Collected
Volume of distribution: Not Collected
Clearance: Not Collected
Notes: Not Collected
Assessment, Analysis, and Discussion
Completion: Study completed
Completed Study Assessment: Inactive
Pharmacokinetics / Pharmacodynamics: Correlative Endpoints NotMet
Investigator’s analysis: Inactive because results did notmeet primary endpoint
Discussion
The Bayesian formulation permitted estimation of the probability of achieving the target response rate for
each subtype after each response evaluation. By allowingmultiple looks at the data, this design stopped the
trial after considering theprobability of achieving the target response rate andaccrual rate. Because this de-
sign did not specify a rule for declaring the treatment as “active,” a direct comparison with a standard two-
stage phase II design is not appropriate. The decision to close the EWS and chondrosarcoma subtype arms
wasbased, inpart,onslowaccrual andwassupportedby the lowprobabilityofachieving the target response
rate. The rate of enrollment, rather than the statistical design, had a significant effect on the trial duration.
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Table
Click here to access other published clinical trials.
Table 1. Subject Characteristics.
Osteosarcoma Ewing Sarcoma Chondro-sarcoma Total
N 14 14 25 53
Female;Male 8:6 2:12 10:15 20:33
Median Age (years) 36.2 25.9 55.2 37.7
(Range) (12.9–75.8) (16.9–42.2) (25.9–77.6) (12.9–77.6)
Race/Ethnicity
White 10 12 20 42
Black 2 0 1 3
Hispanic 1 2 4 1
Other 1 0 0 1
No. Prior chemotherapy
regimens
Median (range) 2 (1–3) 2 (1–3) 0 (0–2) 1 (0–3)
No. cycles gemcitabine
docetaxel
Median (range) 2 (1–15) 2 (1–12) 4 (1–21) 3 (1–21)
Total cycles delivered 53 43 130 226
Best Response
CR 0 0 0
PR 1 2 2
SD post Cycle 4 3 6 14
SD post Cycle 8 0 0 2
PD 13 12 21
